Info@ThinkPinkRocks.org

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

View article:
Johnson & Johnson completes acquisition of Alios BioPharma

Scroll to Top